Sort   by:  
 Page size 
UnknownIs the Capsaicin 179 mg (8% w/w) Cutaneous Patch an Appropriate Treatment Option for Older Patients with Peripheral Neuropathic Pain?
Not available
S-EPMC10981873 | biostudies-literature
UnknownTapentadol Prolonged Release for Long-Term Treatment of Pain in Children.
Not available
S-EPMC7725093 | biostudies-literature
UnknownCebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial.
Not available
S-EPMC5761752 | biostudies-literature
UnknownRationale and design of SAVI-AoS: A physiologic study of patients with symptomatic moderate aortic valve stenosis and preserved left ventricular ejection fraction.
Not available
S-EPMC9157233 | biostudies-literature
UnknownCost-Effectiveness of a High-Concentration (179 mg) Capsaicin Patch for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland.
Not available
S-EPMC12484434 | biostudies-literature
UnknownReal-world 12-month outcomes of repeated high-concentration capsaicin patch in chemotherapy-induced peripheral neuropathy: results from the CASPAR study.
Not available
S-EPMC12711474 | biostudies-literature
UnknownDirect conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
Not available
S-EPMC5071659 | biostudies-literature
UnknownPopulation Pharmacokinetics of Tapentadol in Children from Birth to <18 Years Old.
Not available
S-EPMC7700087 | biostudies-literature
UnknownAssessment of the Abuse Potential of Cebranopadol in Nondependent Recreational Opioid Users: A Phase 1 Randomized Controlled Study.
Not available
S-EPMC6319565 | biostudies-literature
UnknownPopulation pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population.
Not available
S-EPMC6800464 | biostudies-literature
Sort   by:  
 Page size